169 related articles for article (PubMed ID: 36907775)
1. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
[TBL] [Abstract][Full Text] [Related]
2. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
[TBL] [Abstract][Full Text] [Related]
3. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema.
Soto B; Ahmed H; Pillai M; Park SS; Ploszaj M; Reece J; Taluru H; Bobrow D; Yu H; Lafortune P; Jundi B; Costanzo L; Dabo AJ; Foronjy RF; Mueller C; Ohlmeyer M; Geraghty P
Am J Respir Cell Mol Biol; 2023 Nov; 69(5):533-544. PubMed ID: 37526463
[TBL] [Abstract][Full Text] [Related]
6. Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.
Bownes LV; Marayati R; Quinn CH; Beierle AM; Hutchins SC; Julson JR; Erwin MH; Stewart JE; Mroczek-Musulman E; Ohlmeyer M; Aye JM; Yoon KJ; Beierle EA
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454859
[TBL] [Abstract][Full Text] [Related]
7. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
[TBL] [Abstract][Full Text] [Related]
8. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
9. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
11. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
12. GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.
Pei Y; Yao Q; Yuan S; Xie B; Liu Y; Ye C; Zhuo H
Oncotarget; 2016 Nov; 7(47):77890-77901. PubMed ID: 27788486
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
[TBL] [Abstract][Full Text] [Related]
14. Babao Dan is a robust anti-tumor agent via inhibiting wnt/β-catenin activation and cancer cell stemness.
Xie X; Chen J; Wo D; Ma E; Ning Y; Peng J; Zhu W; Ren DN
J Ethnopharmacol; 2021 Nov; 280():114449. PubMed ID: 34332067
[TBL] [Abstract][Full Text] [Related]
15. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
16. Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation.
Jin J; Jin J; Woodfield SE; Patel RH; Jin NG; Shi Y; Liu B; Sun W; Chen X; Yu Y; Vasudevan SA
Oncol Rep; 2019 Jan; 41(1):143-153. PubMed ID: 30320362
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
18. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
[TBL] [Abstract][Full Text] [Related]
19. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
